CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

JNJ-4528 Boasts High Response Rate in Relapsed/Refractory Myeloma

February 6th 2020

Deepu Madduri, MD, discusses the results of the CARTITUDE-1 trial and the next phase of development with JNJ-4528.

Dr. Voorhees on the Role of CAR T-Cell Therapy in Multiple Myeloma

February 5th 2020

Peter Voorhees, MD, discusses the role of CAR T-cell therapy in multiple myeloma.

Dr. Kansagra on Expanding Role of CAR T-Cell Therapy in Lymphoma and Multiple Myeloma

February 4th 2020

Ankit Kansagra, MD, discusses the expanding role of CAR T-cell therapy in lymphoma and multiple myeloma.

CAR T-Cell Products Among Top Advances in Non-Hodgkin Lymphoma

February 1st 2020

Praveen Ramakrishnan, MD, spotlights some of the exciting data recently presented across the spectrum of non-Hodgkin lymphoma treatment.

Priority Review in RET Fusion+ NSCLC and Thyroid Cancers, Breakthrough Status in MDS, and More

January 30th 2020

MCL: FDA Approval of a Second-Generation BTK Inhibitor

January 30th 2020

CAR T-Cell Therapy and the Future Management of MCL

January 30th 2020

Mantle Cell Lymphoma: Chemotherapy-Free Treatment Options

January 30th 2020

BTK Inhibitors in MCL: AEs, Specificity, and Interactions

January 30th 2020

Selecting a BTK Inhibitor for Mantle Cell Lymphoma

January 30th 2020

Updates in Management of Mantle Cell Lymphoma

January 30th 2020

CAR T-Cell Therapy Continues to Generate Positive Results in Hematologic Cancers

January 29th 2020

Ankit Kansagra, MD, discusses the evolving use of CAR T-cell therapy in multiple myeloma and lymphoma.

T-Cell Immunotherapy Pioneer Seeks New Direction for Solid Tumors

January 11th 2020

CAR T cells are a highly active field of investigation, with many companies at work on formulations they hope to bring to market, but these agents have limitations, particularly with metastasized solid tumors.

Dr. Wong on Investigational CAR T-Cell Products in Multiple Myeloma

January 3rd 2020

Sandy Wong, MD, discusses investigational CAR T-cell products in relapsed/refractory multiple myeloma.

CAR T-Cell Therapy as an Outpatient Treatment Option

December 23rd 2019

Anticipation of ZUMA-7 Results

December 23rd 2019

Next-Generation CAR T Therapy

December 23rd 2019

Expanded Use of CAR T Therapy in Hematologic Malignancies

December 23rd 2019

The TRANSCEND-NHL-001 Trial

December 23rd 2019

CAR T Associated Cytokine Release Syndrome

December 23rd 2019